Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

In Stock

Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) protects against 13 types of pneumococcal bacteria that cause serious infections like pneumonia and meningitis. It strengthens the immune system using advanced conjugate technology for long-lasting protection. Suitable for infants, children, and adults, this vaccine ensures safety, effectiveness, and reduced risk of severe illness. It plays a key role in routine immunization and public health protection.

Category: Vaccines

Description
Specification

Description

Pneumococcal 13-valent Vaccine (Diphtheria CRM197 Protein) provides strong and reliable protection against serious infections caused by Streptococcus pneumoniae. This advanced vaccine actively stimulates the immune system to defend the body against 13 harmful pneumococcal serotypes responsible for diseases such as pneumonia, meningitis, and bacteremia. Healthcare professionals recommend this vaccine for infants, young children, older adults, and individuals with weakened immunity.

The formulation uses CRM197, a non-toxic diphtheria protein, as a carrier to enhance the immune response. This conjugation allows the body to recognize the bacterial components more effectively and build long-lasting immunity. By promoting a stronger immune reaction, the vaccine reduces the risk of severe infections and related complications.

Doctors Pneumococcal 13-valent Vaccine CRM197 Injection in routine immunization schedules to ensure early protection, especially in children under five years and elderly individuals. It helps lower hospitalization rates and supports better health outcomes by preventing life-threatening pneumococcal diseases. The vaccine also contributes to community protection by reducing the spread of infection.

Manufacturers produce this Pneumococcal 13-valent Vaccine (Diphtheria CRM197 Protein) Injection under strict quality standards to ensure safety, consistency, and effectiveness. Most individuals tolerate it well, with minimal and mild side effects. Its proven clinical performance makes it a trusted choice in preventive healthcare.

Regular vaccination with this conjugate vaccine plays a key role in reducing the global burden of pneumococcal infections. It strengthens individual immunity while supporting public health efforts. Timely administration ensures optimal protection, helping individuals stay healthy and protected from serious bacterial diseases. This vaccine uses an innovative conjugate technology that links pneumococcal polysaccharides with CRM197, a harmless diphtheria-derived protein. This combination significantly enhances the immune response, allowing the body to recognize harmful bacteria more efficiently and build long-lasting protection. As a result, the vaccine not only prevents infection but also reduces the severity of illness if exposure occurs.